ACELRX PHARMACEUT. DL-01 (R5XA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.44 Million ≈ $-2.85 Million USD) by net assets (€17.04 Million ≈ $19.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See R5XA net asset quality index to measure how much of total assets are equity-financed.
ACELRX PHARMACEUT. DL-01 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ACELRX PHARMACEUT. DL-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ACELRX PHARMACEUT. DL-01 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
ACELRX PHARMACEUT. DL-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Incross Co. Ltd
KQ:216050
|
-0.036x |
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
-0.078x |
|
Cassiar Gold Corp
V:GLDC
|
-0.220x |
|
Inventus Mining Corp
V:IVS
|
4.498x |
|
S H L Telemedicine Ltd
SW:SHLTN
|
0.014x |
|
RS GROUP PLC
LSE:RS1
|
0.087x |
|
KLX Energy Services Holdings Inc
NASDAQ:KLXE
|
-0.224x |
|
Youlife Group Inc. American Depositary Shares
NASDAQ:YOUL
|
N/A |
Annual Cash Flow Conversion Efficiency for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ACELRX PHARMACEUT. DL-01.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €17.04 Million ≈ $19.92 Million |
€-11.36 Million ≈ $-13.29 Million |
-0.667x | +57.92% |
| 2024-12-31 | €8.00 Million ≈ $9.35 Million |
€-12.68 Million ≈ $-14.83 Million |
-1.585x | -27.82% |
| 2023-12-31 | €14.11 Million ≈ $16.49 Million |
€-17.49 Million ≈ $-20.45 Million |
-1.240x | +4.51% |
| 2022-12-31 | €21.81 Million ≈ $25.50 Million |
€-28.33 Million ≈ $-33.12 Million |
-1.299x | -255.38% |
| 2021-12-31 | €-35.89 Million ≈ $-41.96 Million |
€-30.00 Million ≈ $-35.08 Million |
0.836x | -- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more